Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976760 | 0.95 | PDK2 (0.34) | PDK2TGFBR1ADORA1ADORA2AMAPT | |
| SCHEMBL9976764 | 0.92 | PDK2 (0.36) | PDK2TGFBR1L3MBTL1 | |
| SCHEMBL9976749 | 0.86 | PDK2 (0.35) | PDK2ADORA1ADORA2AMAPT | |
| SCHEMBL24654452 | 0.85 | PDK2 (0.36) | PDK2TGFBR1 | |
| SCHEMBL12429149 | 0.83 | PDK2 (0.37) | PDK2 | |
| SCHEMBL9976741 | 0.83 | PDK2 (0.35) | PDK2MAPT | |
| SCHEMBL9976739 | 0.82 | PDK2 (0.35) | PDK2 | |
| SCHEMBL9976732 | 0.80 | COMT (0.39) | PDK2L3MBTL1 | |
| SCHEMBL9980024 | 0.80 | PDK2 (0.42) | PDK2TGFBR1 | |
| SCHEMBL17875437 | 0.80 | PDK2 (0.40) | PDK2ADORA1ADORA2AMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877354-B2 | Heterocyclic compound and organic light-emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8877354-B2 | Heterocyclic compound and organic light-emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-06-21 | — | — | US | disclosed |
| WO-2011024391-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | ORC3, CYP1A1, CRY1 | PDK2 523/4885TGFBR1 1040/4885ADORA1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.